Skip to content

Clinical trials

Recruiting Observational Stomach Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Stomach Neoplasms Phase: Observational Status: Recruiting Clear all

152 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20023
20081
20111
20135
20163
20171
20184
20192
20206
202115
202211
202317
202428
202533
202622

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting152

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University6
City of Hope Medical Center4
Jichao Qin4
Nanfang Hospital, Southern Medical University4
Tianjin Medical University Cancer Institute and Hospital4
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology4
Zhejiang Cancer Hospital4
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo3
Chinese University of Hong Kong3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Stomach Neoplasms152
Esophageal Neoplasms24
Colorectal Neoplasms22
Lung Neoplasms20
Pancreatic Neoplasms20
Breast Neoplasms18
Neoplasms14
Colonic Neoplasms12
Carcinoma, Hepatocellular11
Liver Neoplasms9

Trials

Showing 1 to 25 of 152. Each trial links to its page on Pharma Observatory.

52 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.